Tuesday, October 06, 2020 4:30:38 AM
A Chinese drugmaker, which is collaborating with AstraZeneca PLC on production of a coronavirus vaccine, has won approval from Chinese regulators to start testing one of its own vaccine candidates at home.
Shenzhen Kangtai Biological Products Co., one of the world´s largest producers of hepatitis B vaccines, said Tuesday in a stock-exchange filing it will begin testing its coronavirus vaccine candidate on people immediately, after it was found to protect mice and monkeys from the new virus.
The company, based in the southern Chinese city of Shenzhen, didn´t say where it would conduct the trials. Because China has largely brought the virus under control at home, its drugmakers have had to venture to other countries where coronavirus is still a problem to run larger scale advanced clinical trials. Their initial trials to test for safety, however, have generally taken place in China.
Shenzhen Kangtai also said it has already built a new facility for producing the vaccine, for which it will seek separate regulatory certification.
Dozens of drugmakers and medical institutions around the world are running human clinical tests on 40 Covid-19 vaccine candidates, according to the World Health Organization, in a global effort to fight a pandemic that has now killed more than one million people.
Chinese institutions are behind many of those experimental vaccines and are responsible for four of the 10 candidates in the final stages of testing.
At the same time, Beijing has overseen an unorthodox campaign to inject members of its military--as well as hundreds of thousands of employees of state-owned enterprises, journalists and other people--with homegrown vaccine candidates before their clinical trials are complete.
In August, the Cambridge, U.K.-based AstraZeneca and Shenzhen Kangtai said they would produce at least 200 million doses of the British drugmaker´s experimental Covid-19 vaccine for the Chinese market by the end of 2021.
Shenzhen Kangtai aims to finish building a facility to produce AstraZeneca´s vaccine by the end of the year, according to Tuesday´s filing.
AstraZeneca´s coronavirus vaccine candidate is based on a relatively new technique known as an adenovirus vector, which acts as a carrier for the portion of the vaccine intended to trigger an immune response against the coronavirus.
The separate Covid-19 vaccine candidate for which Shenzhen Kangtai recently won Chinese regulatory approval is based on a more-established method of producing vaccines. It involves growing viruses in petri dishes and then weakening them for use on humans.
Such so-called inactivated vaccines are similar to three Chinese candidates the government approved for domestic emergency use beginning in July. Chinese drugmakers have made less headway compared with their Western peers in more-advanced methods drawing upon genetics technology.
A goal is a dreams deadline...what is your goal?
´¯`·.¸¸.·´¯`·.¸ ><((((((º>
`·.¸¸.·´¯`·.¸¸.·´¯`·.¸ ><((((º>
Recent AZN News
- Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial • Business Wire • 09/23/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/23/2024 10:44:42 AM
- Apollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and More • IH Market News • 09/23/2024 10:32:25 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/23/2024 10:27:18 AM
- FLUMIST approved for self-administration in the US • Business Wire • 09/20/2024 08:34:00 PM
- FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis • Business Wire • 09/18/2024 11:00:00 AM
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 • GlobeNewswire Inc. • 09/17/2024 03:22:47 PM
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial • Business Wire • 09/16/2024 11:00:00 AM
- IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial • Business Wire • 09/15/2024 02:30:00 PM
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases • Business Wire • 09/13/2024 02:00:00 PM
- SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing • PR Newswire (US) • 09/10/2024 02:28:00 PM
- SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing • PR Newswire (US) • 09/10/2024 02:16:00 PM
- Apple Loses EU Dispute; Google’s $2.7 Billion Fine Upheld; Oracle Shares Surge 9% • IH Market News • 09/10/2024 10:02:31 AM
- Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial • Business Wire • 09/09/2024 05:50:00 PM
- Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial • Business Wire • 09/08/2024 04:25:00 PM
- Qualcomm Develops Mixed Reality Glasses; Verizon to Boost Dividend, Eyes Acquisition; Samsonite Plans US Dual Listing • IH Market News • 09/05/2024 10:11:35 AM
- AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024 • Business Wire • 09/03/2024 11:00:00 AM
- Cruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1% • IH Market News • 08/23/2024 12:20:26 PM
- IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery • Business Wire • 08/16/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/16/2024 10:21:46 AM
- IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US • Business Wire • 08/15/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/30/2024 10:26:06 AM
- Toyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom Chatbots • IH Market News • 07/30/2024 10:00:51 AM
- Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial • Business Wire • 07/29/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/29/2024 10:00:43 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM